Salix should be bought ahead of catalysts, says Sterne Agee Sterne Agee believes that the upcoming FDA Advisory Committee on Relistor, scheduled for June 11-12, and the TARGET 3 clinical trial data on Xifaxan, expected in early July, provide important near-term catalysts for Salix. The firm recommends that investors buy Salix ahead of these events. It increased its price target on the stock to $130 from $126.
Salix upgraded to Buy from Neutral at UBS UBS upgraded Salix Pharmaceuticals to Buy saying it believes management has a better handle on inventory levels than investors think. The sees opportunity at current share levels and lowered its price target for shares to $116 from $160.